Akademik Veri Yönetim Sistemi
ECTRIMS, Vienna, Avusturya, 13 - 15 Kasım 2021, ss.276, (Özet Bildiri)
Introduction: Ocrelizumab has been shown to be an effective treatment of both relapsing multiple sclerosis (RMS) and progressive multiple sclerosis (PMS). Aims: To evaluate cognitive function changes with ocrelizumab as a part of treatment effectiveness. Methods: The data of 28 RMS and 100 PMS (primary or secondary MS) was investigated in this prospective study. Cognitive performance was assessed using Brief International Cognitive Assessment in Multiple Sclerosis (BICAMS- SDMT; Symbol Digit Modalities Test; CVLT-II; California Verbal Learning Test second edition; BVMT-R; Brief Visuospatial Memory Test Revised) compared to healthy controls. Each test was done twice; before ocrelizumab initation and at the sixth month. The data was analyzed with Mann-Whitney U test. Results:. CVLT-II scores were significantly increased in progressive form, at month 6 according to baseline assessment (p<0,05) but no significant difference was observed in relapsing form. When two forms were compared to each other, the improvement in CVLT-II scores was significantly different in PMS over RMS. No significant differences were observed between the baseline and at month 6 in term of SDMT, BVMT-R scores in both forms(p>0.05). Conclusions: Ocrelizumab may improve verbal skills in PMS in early phase of treatment. This finding is worth studying in detail and encourages further research to determine its causes. Our data also confirm that there is no early cognitive impairment in relapsing MS under ocrelizumab treatment.